In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor development. Because their expression is exclusive to cancer cells and their elimination induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However, specifically targeting the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Lage, M., Torres-Ruiz, R., Puig-Serra, P., Moreno-Gaona, P., Martin, M. C., Moya, F. J., Quintana-Bustamante, O., Garcia-Silva, S., Carcaboso, A. M., Petazzi, P., Bueno, C., Mora, J., Peinado, H., Segovia, J. C., Menendez, P., Rodriguez-Perales, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544871/
https://www.ncbi.nlm.nih.gov/pubmed/33033246
http://dx.doi.org/10.1038/s41467-020-18875-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544871/
https://www.ncbi.nlm.nih.gov/pubmed/33033246
http://dx.doi.org/10.1038/s41467-020-18875-x

Ejemplares similares